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LETTERS
washing facilities were located near 
the lamb-petting area, and consider-
able effort was required to locate a 
handwashing basin in the wildlife 
center complex. Several alcohol hand 
sanitizers were located on site, but the 
microbicidal effects on Cryptosporid-
ium spp. are insufﬁ  cient to prevent in-
fection, especially after direct contact 
with livestock (4,5).
After publication of the outbreak 
report, an assessment of hand-washing 
and hygiene facilities elsewhere in 
Scotland found them to be suboptimal 
and that stronger education, regula-
tion, and other control measures were 
needed to protect the public. Recent 
Escherichia coli O157 outbreaks in 
England have accentuated the unre-
solved issues for UK petting farms 
concerning hand hygiene and zoonotic 
infections (6).
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Increase in 
Pneumococcus 
Macrolide 
Resistance, USA 
To the Editor: Jenkins and Far-
rell reported an increase in the propor-
tion of macrolide-resistant Streptococ-
cus pneumoniae isolates in the United 
States (1). They mentioned increased 
use and inappropriate prescription of 
macrolides as potential explanations 
for the increase in macrolide resis-
tance and expressed doubts, stating 
“which (if any) of these factors might 
explain the trends here are not clear.” 
Although the spread of antimicrobial 
drug resistance is a complex issue with 
many contributing factors, we believe 
that the role of macrolide use should 
not be understated.
Several studies in Europe have 
provided evidence for a relationship 
between macrolide use and resis-
tance. Macrolide exposure leads to 
emergence of macrolide resistance on 
the individual level, and countries in 
Europe with higher outpatient sales 
of macrolides have more macrolide-
resistant pneumococci (2).
Outpatient antimicrobial drug 
use in the United States has decreased 
since 1995–1996, especially among 
children. However, use of azithromy-
cin increased in children, and use of 
macrolides increased in older patients 
from 1995–1996 through 2005–2006 
(3). In this context, it would be sur-
prising that after this increase, pneu-
mococci would show different char-
acteristics in the United States than 
in Europe. A 2001 study showed that 
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Figure. Date of onset of cryptosporidiosis cases reported to Health Protection Scotland and 
date of visit to wildlife center, 2005. LETTERS
increased macrolide use in the United 
States during 1995–1999 coincided 
with a doubling of the proportion of 
macrolide-resistant pneumococci (4), 
and further increases in macrolide 
use since 1999 (3) have contributed 
to the increase in macrolide-resistant 
pneumococci.
Decreased macrolide use has led 
to a decrease in macrolide-resistant 
pneumococci. A yearly seasonal re-
duction in antimicrobial drug pre-
scribing in Israel was associated with 
a decrease in the proportion of antimi-
crobial drug–resistant pneumococci 
that caused acute otitis media (5). With 
the introduction of expanded-valent 
pneumococcal conjugate vaccines, 
there is promise that drug-resistant 
pneumococcal disease can be reduced. 
Nevertheless, judicious use of anti-
microbial drugs and a decrease in un-
necessary prescriptions, as promoted 
by the Get Smart: Know When Anti-
biotics Work (www.cdc.gov/getsmart) 
campaign, are essential to limiting 
selection and spread of antimicrobial 
drug resistance.
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Rapid Antigen 
Test for Pandemic 
(H1N1) 2009 Virus
To the Editor: Drexler et al. re-
cently compared the sensitivity of the 
BinaxNOW Inﬂ  uenza A & B Rapid 
Test (BinaxNOW; Inverness Medi-
cal, Cologne, Germany) with that of 
a real-time reverse transcription–PCR 
(RT-PCR) assay speciﬁ  c for inﬂ  uenza 
A pandemic (H1N1) 2009 virus (1). 
Of 1,838 clinical specimens tested, 
221 were conﬁ   rmed as positive for 
pandemic (H1N1) 2009 by RT-PCR. 
When 144 of these 221 specimens 
were evaluated by using the Binax-
NOW, results were positive for only 
16 (11%).
At onset of the pandemic, we 
evaluated the ﬁ  rst 135 nasopharyngeal 
aspirates submitted to the Regional 
Laboratory of Public Health Haar-
lem, the Netherlands. We compared 
the performance of the BinaxNOW 
for diagnosing inﬂ  uenza  A  (H1N1) 
virus by using molecular detection of 
inﬂ  uenza virus as the reference stan-
dard. Samples were analyzed with a 
general inﬂ   uenza A assay targeting 
the matrix gene (the RespiFinder as-
say) (PathoFinder B.V., Maastricht, 
the Netherlands [2]) and a pandemic 
(H1N1) 2009–speciﬁ   c RT-PCR as-
say targeting the neuraminidase gene 
(3). We tested 135 patient samples (76 
from male patients); mean age of pa-
tients was 32 years (range 0–81 years). 
Samples from 38 (28%) patients had 
positive results in both RT-PCRs, and 
samples from 97 (72%) patients had 
negative results in the matrix gene RT-
PCR and neuraminidase RT-PCR as-
says. Sensitivity and speciﬁ  city were 
estimated to be 47% (18/38, 95% con-
ﬁ  dence interval [CI] 32%–62%) and 
95% (92/97, 95% CI 88%–98%), re-
spectively, for the BinaxNOW antigen 
test. Patients’ ages did not signiﬁ  cantly 
differ between rapid test–positive and 
–negative results.
Our results largely agree with 
those of Vasoo et al. (4) and the Cen-
ters for Disease Control and Preven-
tion (5). Those studies determined that 
the sensitivity of the BinaxNOW com-
pared with nucleic acid ampliﬁ  cation 
tests is ≈40%. The lower sensitivity 
observed by Drexler et al. (1) might 
be because of differences in study type 
(retrospective evaluation compared 
with a prospective cohort in our study), 
sample size, technical factors (with re-
gard to specimen collection, specimen 
transport, and specimen storage), dif-
ferences in the test kit, and differences 
between individual patients (multiple 
categories of age and stages of illness, 
differences in virus shedding).
Many clinicians are not aware of 
the performance of speciﬁ  c  test  de-
vices and rely on test results to make 
clinical decisions. Because negative 
results cannot rule out inﬂ  uenza, this 
test is of little use in a clinical setting 
without appreciation of the limitations 
of the test. However, because the Bi-
naxNOW has reasonable speciﬁ  city, 
it might prove useful in clinical or 
epidemiologic situations in which test 
sensitivity is not critical, e.g., in facil-
ity outbreaks in which multiple speci-
mens are collected to rapidly identify 
the causative organism.
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